User:Mr. Ibrahem/Brexpiprazole

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic used to treat schizophrenia, and major depressive disorder (MDD). In schizophrenia it may be used in those over the age of 12. It may also be used for agitation in people with dementia. It is taken by mouth.

Common side effects include weight gain and a movement disorder known as akathisia. Other side effects may include neuroleptic malignant syndrome, tardive dyskinesia, diabetes, problem gambling, and low white blood cells. Use in older people with dementia increases the risk of death. Safety in pregnancy is unclear. It is believed to work by affecting dopamine, serotonin, and noradrenaline in the brain.

Brexpiprazole was approved for medical use in the United States in 2015 and Europe in 2018. It is not available in the United Kingdom as of 2022. In the United States it costs about 1,200 USD per month as of 2022, regardless of the dose.